Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson's disease.

Typeset version

 

TY  - JOUR
  - Collins LM, Gavin AM, Walsh S, Sullivan AM, Wyatt SL, O'Keeffe GW, Nolan YM, Toulouse A
  - 2014
  - January
  - SpringerPlus
  - Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson's disease.
  - Validated
  - ()
  - 3
  - We have previously demonstrated that mitogen-activated protein kinase phosphatase 1, Mkp1, is expressed in the developing and rat adult substantia nigra and striatum, where it promotes the growth of nigral dopaminergic neurons. Mkp1 may therefore have therapeutic potential for Parkinson's disease. In the present study, we have assessed the expression of Mkp1 and TH in the substantia nigra and striatum of parkinsonian rat models. Expression was measured at 4 and 10 days post-lesion in the 6-hydroxydopamine (6-OHDA) medial forebrain bundle lesion model and after 4, 10 and 28 days in the 6-OHDA striatal lesion model. Our results show that Mkp1 expression was transiently up-regulated in the substantia nigra at 4 days post-6-OHDA administration in the two models while TH expression was decreased at the later time-points examined. These data suggest that Mkp1 may play a role in counteracting the neurotoxic effects of 6-OHDA in nigral dopaminergic neurons.
  - 10.1186/2193-1801-3-205
DA  - 2014/01
ER  - 
@article{V287575620,
   = {Collins LM,  Gavin AM and  Walsh S,  Sullivan AM and  Wyatt SL,  O'Keeffe GW and  Nolan YM,  Toulouse A },
   = {2014},
   = {January},
   = {SpringerPlus},
   = {Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson's disease.},
   = {Validated},
   = {()},
   = {3},
   = {{We have previously demonstrated that mitogen-activated protein kinase phosphatase 1, Mkp1, is expressed in the developing and rat adult substantia nigra and striatum, where it promotes the growth of nigral dopaminergic neurons. Mkp1 may therefore have therapeutic potential for Parkinson's disease. In the present study, we have assessed the expression of Mkp1 and TH in the substantia nigra and striatum of parkinsonian rat models. Expression was measured at 4 and 10 days post-lesion in the 6-hydroxydopamine (6-OHDA) medial forebrain bundle lesion model and after 4, 10 and 28 days in the 6-OHDA striatal lesion model. Our results show that Mkp1 expression was transiently up-regulated in the substantia nigra at 4 days post-6-OHDA administration in the two models while TH expression was decreased at the later time-points examined. These data suggest that Mkp1 may play a role in counteracting the neurotoxic effects of 6-OHDA in nigral dopaminergic neurons.}},
   = {10.1186/2193-1801-3-205},
  source = {IRIS}
}
AUTHORSCollins LM, Gavin AM, Walsh S, Sullivan AM, Wyatt SL, O'Keeffe GW, Nolan YM, Toulouse A
YEAR2014
MONTHJanuary
JOURNAL_CODESpringerPlus
TITLEExpression of endogenous Mkp1 in 6-OHDA rat models of Parkinson's disease.
STATUSValidated
TIMES_CITED()
SEARCH_KEYWORD
VOLUME3
ISSUE
START_PAGE
END_PAGE
ABSTRACTWe have previously demonstrated that mitogen-activated protein kinase phosphatase 1, Mkp1, is expressed in the developing and rat adult substantia nigra and striatum, where it promotes the growth of nigral dopaminergic neurons. Mkp1 may therefore have therapeutic potential for Parkinson's disease. In the present study, we have assessed the expression of Mkp1 and TH in the substantia nigra and striatum of parkinsonian rat models. Expression was measured at 4 and 10 days post-lesion in the 6-hydroxydopamine (6-OHDA) medial forebrain bundle lesion model and after 4, 10 and 28 days in the 6-OHDA striatal lesion model. Our results show that Mkp1 expression was transiently up-regulated in the substantia nigra at 4 days post-6-OHDA administration in the two models while TH expression was decreased at the later time-points examined. These data suggest that Mkp1 may play a role in counteracting the neurotoxic effects of 6-OHDA in nigral dopaminergic neurons.
PUBLISHER_LOCATION
ISBN_ISSN
EDITION
URL
DOI_LINK10.1186/2193-1801-3-205
FUNDING_BODY
GRANT_DETAILS